rare gene mutation anaesthetic canary islands

Rare gene mutation turns anaesthetic into poison

Compiled with the help of artificial intelligence, based on Spanish-language information. Source below the article.

A surgery that never happened

The Venezuelan Hilda Flores had spent months waiting for an operation that would restore movement to her battered right arm. After a “silly” fall down some stairs, she had developed a shoulder problem that stopped her carrying out the simplest everyday tasks. When she finally secured a date in the operating theatre, she could scarcely believe it. Even less could she believe that, minutes before she was due to pass through the doors of the operating room, the anaesthetist Fernando Cassinello stopped her in her tracks to prevent the surgery going ahead. She did not know it, but her ancestry had become a potential danger. In fact, had she slipped into anaesthetic sleep, she could have taken a long time to wake, developed complex brain damage or, in the worst case, died. After that, Flores would become the first person diagnosed in the Canary Islands with a rare mutation that turns anaesthetic gas into a deadly poison.

A mutation found only in people of Venezuelan descent

What Flores suffers from is a mutation of the mitochondrial ND4 gene. It is a rare genetic combination described by science only a year ago which, for now, affects only people of Venezuelan descent. Researchers believe the mutation arose in a woman decades ago in the state of Carabobo. “The incidence in this population is up to 15 times more frequent than in the rest of Venezuela,” says Cassinello, an anaesthetist at the Hospital Universitario Nuestra Señora de Candelaria, who is one of the Spaniards who has worked most actively on research into the gene and on drawing up the new protocols for treating these patients.

How the mutation attacks the body

The mutation in the mitochondrial ND4 gene causes a genetic hypersensitivity to one of the anaesthetic drugs most widely used in operating theatres around the world: sevoflurane. When a patient with this mutation receives the anaesthetic, their mitochondria stop working. Mitochondria are the power stations of our cells and, in particular, of our neurons. If their function is inhibited, even for just a few hours or minutes, the result can be irreversible. “In this case, unfortunately, it is those of the brain that stop, in the basal ganglia, which are key to the functioning of our entire body,” Cassinello summarises. Inducing anaesthetic sleep becomes, in these patients, a potentially life-threatening risk, especially in the youngest children.

An alert passed down the maternal line

“We have had an alert in place for some time over possible complications in patients of Venezuelan maternal descent,” Cassinello explains. Because it is a mutation in mitochondrial DNA, only mothers can pass it on to their sons and daughters. The delicate health alert remained hidden and even denied amid the opaque information provided by the Venezuelan regime over the years, until the country’s socio-economic and political situation drove thousands of people to emigrate en masse to other countries. “Recently in Chile several cases of deaths in children after the use of anaesthesia were described and, from there, research began at an international level,” Cassinello stresses. “We have not been given much information, but we know that there this type of anaesthetic – which is administered as a gas and is more common in children – is no longer used,” he reveals.

The first two cases in the Canary Islands

Hilda Flores’s is the first positive result detected in the Canary Islands out of the roughly 350 tests carried out across the archipelago. The second is her son. “I was very worried that he might have it, but it came back positive and there is nothing we can do, at least now we know,” Flores says. For the patient it has been a before and after in her life. “At the time, when they wouldn’t let me into the operating theatre, I cried and got angry because I had been waiting such a long time, but looking back, I am 100% grateful that they didn’t operate on me that day,” she says.

Forty cases worldwide and a young man in Spain

Some 40 cases have so far been detected worldwide. But one of the most significant occurred in Spain. It is the case of Uri, a 14-year-old boy who lost the ability to speak after anaesthesia. The youngster, who became Spain’s first case of this dangerous mutation, survived the anaesthetic but did so in a wheelchair. His case was studied thanks to the determination of a Spanish biochemist, Eduardo Ruiz Pesini, Professor of Biochemistry at the University of Zaragoza, who has devoted the last 30 years to the study of mitochondrial diseases.

A family history that raised no suspicions

In Flores’s case, although she had never even thought about it until then, there was a history that could have made her suspect something was wrong. “A cousin of mine on my mother’s side had an adverse neurological event years ago when she was only 34,” Flores explains. It happened after an anaesthetic from which she took a long time to wake. When she finally did, she was no longer the same. “She was a very brilliant and professional woman, and her life changed,” Flores recalls. “There may be thousands of people, but we are surely not aware of all of them,” Cassinello reveals.

Almost 700,000 Venezuelans in Spain

According to data from the National Statistics Institute, the total population from Venezuela across Spain stands at 692,316 people, with large concentrations in Madrid and the Canary Islands. At least 19,000 people with Venezuelan nationality live in the archipelago. For all of them, however, there is a therapeutic alternative and an easy solution. Patients with this mutation can be given intravenous or gaseous propofol. “It is true that if we have used the ventilator with gases in the morning, we have to clean it thoroughly so that no traces remain,” Cassinello stresses. In all hospitals in the Canary Islands – under the leadership of the Hospital de La Candelaria – a strategy for managing these patients has also been introduced, which not only sets out a specific treatment but also screening – with a simple blood test – of potential carriers before surgery to reduce risks.

Source

Scroll to Top